On October 26, 2021 Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, reported new data further validating the performance of the Company’s DecisionDx DiffDx-Melanoma test as a highly accurate, ancillary tool to aid in the diagnosis of melanocytic lesions with ambiguous histopathology (Press release, Castle Biosciences, OCT 26, 2021, View Source [SID1234591978]). The data was shared in a poster presentation at The American Society of Dermatopathology (ASDP) 58th Annual Meeting, held virtually Oct. 20-24.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DiffDx-Melanoma is part of Castle’s Comprehensive Diagnostic Offering (CDO), leveraging the strengths of both myPath Melanoma and DiffDx-Melanoma. These two gene expression profile (GEP) tests were designed to provide a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing difficult-to-diagnose melanocytic lesions.

The poster, titled "Performance of the 35 Gene Expression Profile (GEP) Test for Use as an Adjunctive Melanoma Diagnostic Tool in a New Independent Validation Cohort," describes the performance of DiffDx-Melanoma, independent of myPath Melanoma and also as part of the clinical CDO workflow. The poster can be viewed here.

"In clinical practice, difficult-to-diagnose melanocytic lesions often present a challenge for dermatopathologists, particularly when there is hesitation in the diagnosis of melanoma," said Gregory A. Hosler, M.D., Ph.D., dermatopathologist at ProPath in Dallas. "In this study, DiffDx-Melanoma demonstrated its ability to provide dermatopathologists additional information to help guide and potentially increase confidence in a diagnosis, if any uncertainty exists, to help clinicians provide their patients with the most appropriate care."

Study background and findings:

The Institutional Review Board (IRB)-approved study reviewed 644 melanocytic lesions and associated de-identified clinical data from patients ≥ 18 years of age.
Lesions were independently reviewed by at least two dermatopathologists for diagnostic adjudication and included in the study if they received at least two out of three reviews that were diagnostically concordant.
Accuracy metrics demonstrated highly accurate performance of the DiffDx-Melanoma test (96% sensitivity and 92.2% specificity; intermediate result 2.3%) across lesion subtypes reported (excluding spitzoid lesions), including those with subtype discordance.
Separately, the clinical Comprehensive Diagnostic Workflow leverages myPath Melanoma with DiffDx-Melanoma. Clinical order data from June 3-Aug. 31, 2021, showed that this workflow was able to increase the reporting of actionable test results of either benign or malignant from 78% for myPath Melanoma alone to 99% when used in conjunction with DiffDx-Melanoma.
Overall, the study data demonstrated that DiffDx-Melanoma was an accurate, objective ancillary tool that provided information to aid in the diagnosis of melanocytic lesions of uncertain malignant potential, thus enhancing diagnostic confidence and the delivery of clinically, actionable results to healthcare providers.
About Castle Biosciences’ Comprehensive Diagnostic Offering for Difficult-to-Diagnose Melanocytic Lesions

Castle Biosciences’ comprehensive diagnostic offering leverages the strengths of myPath Melanoma and DecisionDx DiffDx-Melanoma. These gene expression profile tests are designed to provide a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing difficult-to-diagnose melanocytic lesions. Of the approximately 2 million suspicious pigmented lesions biopsied annually in the U.S., Castle estimates that approximately 300,000 of those cannot be confidently classified as either benign or malignant through traditional histopathology methods. For these cases, the treatment plan can also be uncertain. Obtaining highly accurate, objective ancillary testing can mean the difference between a path of overtreatment or the risk of undertreatment. Interpreted in the context of other clinical, laboratory and histopathologic information, myPath Melanoma and DecisionDx DiffDx-Melanoma are designed to reduce uncertainty and provide confidence for dermatopathologists and help dermatologists deliver more informed patient management plans.

More information about the test and disease can be found at www.CastleTestInfo.com.